skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ

Abstract

Idelalisib (also known as GS-1101, CAL-101, IC489666, and Zydelig is a PI3Kδ inhibitor that has recently been approved for the treatment of several hematological malignancies. Given its use in human diseases, we needed a clear picture of how idelalisib binds to and inhibits PI3Kδ. Here, our data show that idelalisib is a potent and selective inhibitor of the kinase activity of PI3Kδ. A kinetic characterization clearly demonstrated ATP-competitive inhibition, and several additional biochemical and biophysical assays showed that the compound binds reversibly and noncovalently to the kinase. Lastly, a crystal structure of idelalisib bound to the p110δ subunit of PI3Kδ furthers our understanding of the binding interactions that confer the potency and selectivity of idelalisib.

Authors:
 [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1]
  1. Gilead Sciences, Inc., Foster City, CA (United States)
Publication Date:
Research Org.:
Univ. of California, Berkeley, CA (United States)
Sponsoring Org.:
USDOE Office of Science (SC), Basic Energy Sciences (BES)
OSTI Identifier:
1347695
Alternate Identifier(s):
OSTI ID: 1347696
Grant/Contract Number:  
AC02-05CH11231
Resource Type:
Journal Article: Accepted Manuscript
Journal Name:
Journal of Biological Chemistry
Additional Journal Information:
Journal Volume: 290; Journal Issue: 13; Journal ID: ISSN 0021-9258
Publisher:
American Society for Biochemistry and Molecular Biology
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES; 37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY; CAL-101; enzyme kinetics; enzyme mechanism; enzyme purification; GS-1101; PI3K; PI3Kδ; phosphatidylinositide 3-kinase (PI 3-kinase); surface plasmon resonance (SPR); zydelig

Citation Formats

Somoza, John R., Koditek, David, Villaseñor, Armando G., Novikov, Nikolai, Wong, Melanie H., Liclican, Albert, Xing, Weimei, Lagpacan, Leanna, Wang, Ruth, Schultz, Brian E., Papalia, Giuseppe A., Samuel, Dharmaraj, Lad, Latesh, and McGrath, Mary E. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ. United States: N. p., 2015. Web. doi:10.1074/jbc.m114.634683.
Somoza, John R., Koditek, David, Villaseñor, Armando G., Novikov, Nikolai, Wong, Melanie H., Liclican, Albert, Xing, Weimei, Lagpacan, Leanna, Wang, Ruth, Schultz, Brian E., Papalia, Giuseppe A., Samuel, Dharmaraj, Lad, Latesh, & McGrath, Mary E. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ. United States. https://doi.org/10.1074/jbc.m114.634683
Somoza, John R., Koditek, David, Villaseñor, Armando G., Novikov, Nikolai, Wong, Melanie H., Liclican, Albert, Xing, Weimei, Lagpacan, Leanna, Wang, Ruth, Schultz, Brian E., Papalia, Giuseppe A., Samuel, Dharmaraj, Lad, Latesh, and McGrath, Mary E. 2015. "Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ". United States. https://doi.org/10.1074/jbc.m114.634683. https://www.osti.gov/servlets/purl/1347695.
@article{osti_1347695,
title = {Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ},
author = {Somoza, John R. and Koditek, David and Villaseñor, Armando G. and Novikov, Nikolai and Wong, Melanie H. and Liclican, Albert and Xing, Weimei and Lagpacan, Leanna and Wang, Ruth and Schultz, Brian E. and Papalia, Giuseppe A. and Samuel, Dharmaraj and Lad, Latesh and McGrath, Mary E.},
abstractNote = {Idelalisib (also known as GS-1101, CAL-101, IC489666, and Zydelig is a PI3Kδ inhibitor that has recently been approved for the treatment of several hematological malignancies. Given its use in human diseases, we needed a clear picture of how idelalisib binds to and inhibits PI3Kδ. Here, our data show that idelalisib is a potent and selective inhibitor of the kinase activity of PI3Kδ. A kinetic characterization clearly demonstrated ATP-competitive inhibition, and several additional biochemical and biophysical assays showed that the compound binds reversibly and noncovalently to the kinase. Lastly, a crystal structure of idelalisib bound to the p110δ subunit of PI3Kδ furthers our understanding of the binding interactions that confer the potency and selectivity of idelalisib.},
doi = {10.1074/jbc.m114.634683},
url = {https://www.osti.gov/biblio/1347695}, journal = {Journal of Biological Chemistry},
issn = {0021-9258},
number = 13,
volume = 290,
place = {United States},
year = {Wed Jan 28 00:00:00 EST 2015},
month = {Wed Jan 28 00:00:00 EST 2015}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record

Citation Metrics:
Cited by: 112 works
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

CLAMP©: a biosensor kinetic data analysis program
journal, April 1998


Phosphoinositide 3-kinase   inhibitor suppresses interleukin-17 expression in a murine asthma model
journal, March 2010


A small molecule–kinase interaction map for clinical kinase inhibitors
journal, February 2005


Scaling and assessment of data quality
journal, December 2005


The resurgence of covalent drugs
journal, April 2011


PI3 Kinase δ Is a Key Regulator of Synoviocyte Function in Rheumatoid Arthritis
journal, May 2012


High-Speed Digital Microscopy
journal, August 2000


Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction.
journal, April 1996


Survival of leukemic B cells promoted by engagement of the antigen receptor
journal, November 2001


A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
journal, May 2006


Features and development of Coot
journal, March 2010


The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis
journal, August 2004


The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors
journal, January 2010


PHENIX: a comprehensive Python-based system for macromolecular structure solution
journal, January 2010


Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
journal, March 2014


Role of PI3Kδ and PI3Kγ in inflammatory arthritis and tissue localization of neutrophils
journal, May 2008


Essential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement
journal, March 2003


Essential role for the p110δ phosphoinositide 3-kinase in the allergic response
journal, October 2004


The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis
journal, August 2004


PARP1 exhibits enhanced association and catalytic efficiency with γH2A.X-nucleosome
journal, December 2019


Cavin1 intrinsically disordered domains are essential for fuzzy electrostatic interactions and caveola formation
journal, February 2021


PHENIX: a comprehensive Python-based system for macromolecular structure solution.
text, January 2010


Role of PI3Kδ and PI3Kγ in inflammatory arthritis and tissue localization of neutrophils
journal, May 2008


PI3 Kinase δ Is a Key Regulator of Synoviocyte Function in Rheumatoid Arthritis
journal, May 2012


A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
journal, May 2006


Extending the Range of Rate Constants Available from BIACORE: Interpreting Mass Transport-Influenced Binding Data
journal, August 1998


Essential role for the p110δ phosphoinositide 3-kinase in the allergic response
journal, October 2004


BIRB-796 is not an effective ABL(T315I) inhibitor
journal, October 2005


The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors
journal, January 2010


The resurgence of covalent drugs
journal, April 2011


PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
journal, March 2014


Rapid automated molecular replacement by evolutionary search
journal, February 1999


The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis
journal, October 2004


CLL and NHL: the end of chemotherapy?
journal, May 2014


Phosphoinositide 3-kinase   inhibitor suppresses interleukin-17 expression in a murine asthma model
journal, March 2010


PHENIX: a comprehensive Python-based system for macromolecular structure solution.
text, January 2010


Works referencing / citing this record:

PI3K isoform-selective inhibitors: next-generation targeted cancer therapies
journal, September 2015


Structural Determinants of Isoform Selectivity in PI3K Inhibitors
journal, February 2019


Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib
journal, August 2015


Discovery of the Potent Phosphoinositide 3‐Kinase δ (PI3 K δ) Inhibitors
journal, January 2020


Idelalisib for the treatment of non-Hodgkin lymphoma
journal, January 2016


Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2- c ]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)
journal, June 2016


Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1
journal, February 2017


Analysis of phosphoinositide 3-kinase inhibitors by bottom-up electron-transfer dissociation hydrogen/deuterium exchange mass spectrometry
journal, May 2017


Molecular dynamics insights for PI3K-δ inhibition & structure guided identification of novel PI3K-δ inhibitors
journal, November 2018


Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
journal, May 2019


Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2- c ]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)
journal, June 2016


Analysis of phosphoinositide 3-kinase inhibitors by bottom-up electron-transfer dissociation hydrogen/deuterium exchange mass spectrometry
journal, May 2017


Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
journal, August 2018


Structural Determinants of Isoform Selectivity in PI3K Inhibitors
journal, February 2019


Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
journal, May 2019